nach oben

International Journal of Clinical Oncology

Erschienen in:

06.03.2018 | Original Article

Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver

verfasst von: Fumitaka Ishige, Wataru Takayama, Satoshi Chiba, Isamu Hoshino, Hidehito Arimitsu, Hiroo Yanagibashi, Yosuke Iwatate

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognosis of metastatic recurrent non-small cell lung cancer (NSCLC) is poor, and chemotherapy improves survival by only a few months. The concept of oligo-recurrence, defined as a small number of new lesions at a distant site theoretically curable by local therapy, has recently been proposed for several cancers. To evaluate the possible benefits of surgical resection for oligo-recurrence, we report the outcomes of seven patients who underwent hepatic resection for oligo-recurrence of NSCLC in the liver.

Methods

Among the 2038 patients who underwent resection for NSCLC between January 1997 and December 2015 at the Department of Chest Surgery, Chiba Cancer Center, 7 (0.34%) with oligo-recurrence in the liver underwent hepatectomy. Perioperative data were retrospectively reviewed, including recurrence-free and overall survival.

Results

Primary tumor histopathological types included five cases of squamous cell carcinoma, one case of adenocarcinoma, and one case of large-cell carcinoma. All patients underwent complete tumor resection without complication. The median survival duration following hepatectomy was 24.0 (range 15.2–30.2) months. Four patients were alive at the end of follow-up (23.4–30.2 months), whereas three died between 15.2 and 24.5 months. There was no evidence of second recurrence in two patients.

Conclusions

Hepatectomy may be equally effective as multidisciplinary therapy for oligo-recurrence of NSCLC in the liver.

Yano T, Okamoto T, Haro A et al (2013) Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer 82:431–435CrossRefPubMed

Hishida T, Yoshida J, Aokage K et al (2016) Postoperative oligo recurrence of non-small-cell lung cancer: clinical features and survival. Eur J Cardiothorac Surg 49:847–853CrossRefPubMed

Niibe Y, Hayakawa K (2010) Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 40:107–111CrossRefPubMedPubMedCentral

MacDermed DM, Weichselbaum RR, Salama JK (2008) A rational for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 98:202–206CrossRefPubMed

Hishida T, Nagai K, Yoshida J et al (2006) Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg 131:838–842CrossRefPubMed

Tanvetyanon T, Robinson LA, Schell MJ et al (2008) Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26:1142–1147CrossRefPubMed

Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521CrossRefPubMed

Shimada Y, Saji H, Kakihana M et al (2015) Survival outcomes for oligometastasis in resected non-small cell lung cancer. Asian Cardiovasc Thorac Ann 23:937–944CrossRefPubMed

Yano T, Haro A, Yoshida T et al (2010) Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol 102:852–855CrossRefPubMed

10.

Nagashima A, Abe Y, Yamada S et al (2004) Long-term survival after surgical resection of liver metastasis from lung cancer. Jpn J Thorac Cardiovasc Surg 52:311–313CrossRefPubMed

11.

Adam R, Chiche L, Aloia T et al (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535CrossRefPubMedPubMedCentral

12.

Kornasiewicz O, Ligocka J, Krawczyk M (2015) Liver resection for non-colorectal, non-endocrine liver metastasis. Pol Przegl Chir 3(86):544–551

13.

Di Carlo I, Grasso G, Russello D et al (2003) Liver metastases from lung cancer: is surgical resection justified? Ann Thorac Surg 76:291–293CrossRefPubMed

14.

Ercolani G, Ravaioli M, Grazi GL et al (2006) The role of liver resections for metastases from lung carcinoma. HPB (Oxford) 8:114–115CrossRef

15.

Ileana E, Greillier L, Moutardier V et al (2010) Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon? Lung Cancer 70:221–222CrossRefPubMed

16.

Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317–323CrossRefPubMed

17.

Treat JA, Gonin R, Socinski MA et al (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 21(3):540–547CrossRefPubMed

18.

Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28(36):5240–5246CrossRefPubMed

19.

Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128CrossRefPubMed

Titel: Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver
verfasst von: Fumitaka Ishige
Wataru Takayama
Satoshi Chiba
Isamu Hoshino
Hidehito Arimitsu
Hiroo Yanagibashi
Yosuke Iwatate
Publikationsdatum: 06.03.2018
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1262-y

Springer Medizin

Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver